Evidence map›Paper›PMID 40267160›Full record

ArticlePloS one2025

CureSCi Metadata Catalog-Finding and harmonizing studies for secondary analysis of hydroxyurea discontinuation in sickle cell disease.

Xin Wu, Jeran Stratford, Karen Kesler, Cataia Ives, Tabitha Hendershot, Barbara Kroner, Ying Qin, Huaqin Pan

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Xin WuAnalytics Practice Area, RTI International, Research Triangle Park, United States of America.ORCID 0000-0001-5161-3710
Jeran StratfordAnalytics Practice Area, RTI International, Research Triangle Park, United States of America.
Karen KeslerAnalytics Practice Area, RTI International, Research Triangle Park, United States of America.
Cataia IvesAnalytics Practice Area, RTI International, Research Triangle Park, United States of America.ORCID 0000-0003-3531-7502
Tabitha HendershotAnalytics Practice Area, RTI International, Research Triangle Park, United States of America.
Barbara KronerAnalytics Practice Area, RTI International, Research Triangle Park, United States of America.
Ying QinAnalytics Practice Area, RTI International, Research Triangle Park, United States of America.
Huaqin PanAnalytics Practice Area, RTI International, Research Triangle Park, United States of America.ORCID 0000-0002-7166-108X

Funding

Data Strategy Consortium for the NHLBI Cure Sickle Cell InitiativeOT3HL147798 · NHLBI · RESEARCH TRIANGLE INSTITUTE · PI KRONER, BARBARA L · 2018 to 2025
$18.2M
NHLBI NIH HHS OT3 HL147798
6 · The paper itself

Abstract

objectivesSickle cell disease (SCD) is a rare group of inherited red blood cell disorders that affect hemoglobin, resulting in serious multi-system complications. The limited number of patients available to participate in research studies can inhibit investigating sophisticated relationships. Secondary analysis is a research method that involves using existing data to answer new research questions. Data harmonization enables secondary analysis by combining data across studies, especially helpful for rare disease research where individual studies may be small. The National Heart, Lung, and Blood Institute Cure Sickle Cell Initiative (CureSCi) Metadata Catalog is a web-based tool to identify SCD study datasets for conducting data harmonization and secondary analysis. We present a proof-of-concept secondary analysis to explore factors associated with discontinuation of hydroxyurea, a safe and effective first line SCD therapy, to illustrate the utility of the CureSCi Metadata Catalog to expedite and enable more robust SCD research.

methodsWe performed secondary analysis of SCD studies using a multi-step workflow: develop research questions, identify study datasets, identify variables of interest, harmonize variables, and establish an analysis method. A harmonized dataset consisting of eight predictor variables across five studies was created. Secondary analysis employed a generalized linear model to identify factors that significantly impact hydroxyurea discontinuation.

resultsThe CureSCi Metadata Catalog provided a platform to efficiently find relevant studies and design a harmonization strategy to prepare data for secondary analysis. Multivariate analysis of the harmonized data identified that patients who were female, had a history of blood transfusion therapy, experiencing pain, and had the SC sickle cell genotype are more likely to stop hydroxyurea treatment.

conclusionThis secondary analysis provides a template for how the CureSCi Metadata Catalog expedites dataset discovery of sickle cell studies for identifying relationships between variables or validating existing findings.

Indexed as

Anemia, Sickle CellAntisickling AgentsHydroxyureaMetadataAdultFemaleHumansMaleAntisickling AgentsHydroxyurea

Identifiers

PMID40267160
PMCPMC12017531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.